首页> 外文期刊>EBioMedicine >The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial
【24h】

The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial

机译:冈比亚无症状寄生虫携带者中不同剂量单用伯氨喹与双氢青蒿素-哌喹的杀细胞杀灭功效:一项随机对照试验。

获取原文
       

摘要

Background: Asymptomatic low-density gametocyte carriers represent the majority of malaria-infected individuals. However, the impact of recommended treatment with single low dose of primaquine and an artemisinin-based combination therapy to reduce transmission in this group is unknown. Methods: This was a four-arm, open label, randomized controlled trial comparing the effect of dihydroartemisinin-piperaquine (DHAP) alone or combined with single dose of primaquine (PQ) at 0.20mg/kg, 0.40mg/kg, or 0.75mg/kg on Plasmodium falciparum gametocytaemia, infectiousness to mosquitoes and hemoglobin change in asymptomatic, malaria-infected, glucose-6-phosphate dehydrogenase (G6PD) normal individuals. Randomization was done using a computer-generated sequence of uneven block sizes with codes concealed in sequentially numbered opaque envelopes. The primary endpoint was the prevalence of P. falciparum gametocytemia at day 7 of follow-up determined by quantitative nucleic acid sequence based assay and analysis was by intention to treat. The trial has been concluded (registration number: NCT01838902; https://clinicaltrials.gov/ct2/show/NCT01838902). Results: A total of 694 asymptomatic, malaria-infected individuals were enrolled. Gametocyte prevalence at day 7 was 37.0% (54/146; 95% CI 29.2-45.4), 19.0% (27/142; 95% CI 12.9-26.4), 17.2% (25/145; 95% CI 11.0-23.5) and 10.6% (15/141; 95% CI 6.1-16.9) in the DHAP alone, 0.20mg/kg, 0.40mg/kg, and 0.75mg/kg PQ arms, respectively. The main adverse events reported include headache (130/471, 27.6%), cough (73/471, 15.5%), history of fever (61/471, 13.0%) and abdominal pain (57/471, 12.1%). There were five serious adverse events however, none was related to the interventions. Interpretation: A single course of PQ significantly reduces gametocyte carriage in malaria-infected asymptomatic, G6PD-normal individuals without increasing the risk of clinical anemia. The limited number of successful mosquito infections suggests that post-treatment transmission potential in this asymptomatic population is low.
机译:背景:无症状的低密度配子体细胞携带者是大多数疟疾感染者的代表。然而,在该组中推荐的单次低剂量伯氨喹和基于青蒿素的联合治疗以减少传播的推荐治疗的影响尚不清楚。方法:这是一项四臂,开放标签,随机对照试验,比较了双氢青蒿素-哌喹(DHAP)单独使用或与单剂量伯氨喹(PQ)联合使用0.20mg / kg,0.40mg / kg或0.75mg的疗效/ kg,用于无症状,疟疾感染,葡萄糖-6-磷酸脱氢酶(G6PD)正常个体的恶性疟原虫配子体细胞增多症,蚊子的传染性和血红蛋白变化。使用计算机生成的不规则块大小序列进行随机化,代码隐藏在顺序编号的不透明信封中。主要终点是在随访的第7天,通过基于定量核酸序列的测定确定了恶性疟原虫配子细胞瘤的患病率,并通过有意治疗进行了分析。该试验已经结束(注册号:NCT01838902; https://clinicaltrials.gov/ct2/show/NCT01838902)。结果:共有694名无症状,疟疾感染者入组。第7天的配子细胞患病率为37.0%(54/146; 95%CI 29.2-45.4),19.0%(27/142; 95%CI 12.9-26.4),17.2%(25/145; 95%CI 11.0-23.5)和分别在DHAP,0.20mg / kg,0.40mg / kg和0.75mg / kg PQ臂中分别占10.6%(15/141; 95%CI 6.1-16.9)。报告的主要不良事件包括头痛(130/471,27.6%),咳嗽(73/471,15.5%),发烧史(61/471,13.0%)和腹痛(57/471,12.1%)。有五种严重不良事件,但与干预措施无关。解释:PQ的一个疗程可显着降低疟疾感染的无症状,G6PD正常个体的配子细胞转运,而不会增加临床贫血的风险。成功的蚊子感染数量有限,表明该无症状人群的治疗后传播潜力很低。

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号